Search results for ☑ Cia
-
Acacia Pharma Expands US Commercial Operations for BAREMSIS® with Four Key Appointments
April 11, 2018 -
Acacia Pharma Expands US Commercial Operations for BAREMSIS® with Four Key Appointments
April 11, 2018 -
Acacia Pharma announces positive results from its fourth and final pivotal trial of Baremsis™ for the rescue treatment of PONV
February 13, 2017 -
Acacia Pharma reports positive results from study of BAREMSIS™
January 5, 2016 -
Acacia Pharma’s Baremis® Prevents Post-Operative Nausea And Vomiting In High-Risk Patients
March 15, 2018 -
Acacia Pharma announces positive results from a pivotal phase 3 trial of Baremsis™ for the treatment of post-operative nausea & vomiting
August 12, 2016 -
Acacia Pharma initiates second phase e treatment trial with BAREMSIS™, expects NDA filing in 2016
March 21, 2016 -
Acacia Pharma: Dr Patrick Vink to Succeed Ian Kent as Non-Executive Chairman
December 3, 2015 -
Acacia Pharma Group raises €40m at IPO for US growth
March 2, 2018 -
Xconomy
Beam Therapeutics Promotes Giuseppe Ciaramella to President
January 24, 2020 -
GlobeNewswire
Apellis Pharmaceuticals Expands Leadership Team, Appoints Lucia Celona as Chief People Officer
July 22, 2019 -
GlobeNewswire
Acacia Pharma Launches BYFAVO™ (remimazolam) in the United States for Procedural Sedation in Adults Undergoing Medical Procedures Lasting 30 Minutes or Less
January 28, 2021 -
GlobeNewswire
Acacia Pharma Advances Preparations for US Launch of BARHEMSYS®
July 27, 2020 -
GlobeNewswire
Acacia Pharma Announces Positive Phase 3 Barhemsys® Rescue Treatment Data To Be Presented At The Annual Congress Of Enhanced Recovery And Perioperative Medicine
April 25, 2019 -
GlobeNewswire
Acacia Pharma Announces Initiation of Pivotal Study of Byfavo® in Pediatric Procedural Sedation
September 16, 2021 -
GlobeNewswire
Acacia Pharma Announces Successful Completion of BARHEMSYS® Post-approval Requirement Study in Patients with Severe Renal Impairment
December 13, 2021 -
GlobeNewswire
Acacia Pharma Announces US FDA Approval of BARHEMSYS® (amisulpride) for the Treatment and Prevention of Postoperative Nausea and Vomiting (PONV)
February 27, 2020 -
GlobeNewswire
Acacia Pharma Announces Changes to its Officers and Board of Directors
March 2, 2020 -
GlobeNewswire
Acacia Pharma Announces New BARHEMSYS® PDUFA Target Date of 26 February 2020
September 26, 2019 -
GlobeNewswire
Acacia Pharma Announces Brief Extension of FDA Review Period for NDA for BYFAVO™, an Ultra-short Acting and Reversible Anesthetic for Procedural Sedation
March 12, 2020 -
GlobeNewswire
Ultragenyx and Kyowa Kirin Announce U.S. FDA Approval of Crysvita® (burosumab) for the Treatment of Tumor-Induced Osteomalacia (TIO)
June 18, 2020 -
GlobeNewswire
Acacia Pharma Announces Supportive Cardiac Safety Data for BARHEMSYS™
January 23, 2019 -
GlobeNewswire
Acacia Pharma Announces US FDA Approval of BYFAVO™ (remimazolam) for injection for the Induction and Maintenance of Procedural Sedation
July 2, 2020 -
Reuters
Acacia Pharma Partners With Cosmo Pharmaceuticals
January 10, 2020 -
GlobeNewswire
Acacia Pharma wins BEL Small Company of the Year for the second consecutive year
January 20, 2021 -
GlobeNewswire
Acacia Pharma announces BYFAVO™ (remimazolam), its Newly Approved Product for Procedural Sedation, Clears Final Hurdle on Path to Commercial Launch in the US
October 6, 2020 -
GlobeNewswire
Acacia Pharma Assigned US License for BYFAVO™ (remimazolam) by Cosmo Pharmaceuticals NV
July 15, 2020 -
GlobeNewswire
Acacia Pharma Founder Dr. Julian Gilbert steps down – Michael Bolinder, Chief Commercial Officer, becomes CEO in Planned Succession
July 18, 2019 -
GlobeNewswire
Ultragenyx and Kyowa Kirin Announce FDA Acceptance and Priority Review Designation of Supplemental Biologics License Application for Crysvita® (burosumab) for Tumor-Induced Osteomalacia (TIO)
February 27, 2020 -
GlobeNewswire
Ultragenyx and Kyowa Kirin Announce Intent to Submit Supplemental Biologics License Application to U.S. FDA for Crysvita® (burosumab) in Tumor-Induced Osteomalacia (TIO)
September 10, 2019 -
Aclaris Therapeutics International and Rigel Pharmaceuticals Sign License Agreement for JAK Inhibitors to Treat Skin Disorders
September 9, 2015 -
Aclaris Therapeutics International and Rigel Sign License Agreement for JAK Inhibitors to Treat Skin Disorders
October 9, 2015 -
peerTransfer expands, rebrands as Flywire
September 28, 2015